

# Turkey

Population 2015

79 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.74 (0.63–0.85)	0.94 (0.8–1.1)
Mortality (HIV+TB only)	0.015 (<0.01–0.044)	0.02 (0–0.06)
Incidence (includes HIV+TB)	14 (12–17)	18 (16–21)
Incidence (HIV+TB only)	0.097 (0.082–0.11)	0.12 (0.1–0.15)
Incidence (MDR/RR-TB)**	0.71 (0.6–0.83)	0.9 (0.76–1.1)

## Estimated TB incidence by age and sex (thousands)\*, 2015

	0-14 years	> 14 years	Total
Females	0.64 (0.38–0.9)	5.7 (4.3–7.2)	6.4 (4.7–8.1)
Males	0.6 (0.41–0.8)	7.5 (5.8–9.1)	8.1 (6.2–9.9)
Total	1.2 (0.92–1.6)	13 (12–14)	14 (12–17)

## TB case notifications, 2015

Total cases notified	12 772
Total new and relapse	12 550
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	70%
- % pulmonary	64%
- % bacteriologically confirmed among pulmonary	77%

## Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.05 (0.04–0.06)

## TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	59	<1%
- on antiretroviral therapy	54	92%

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			440 (390–490)
Estimated % of TB cases with MDR/RR-TB	3.6% (3.1–4.2)	21% (17–24)	
% notified tested for rifampicin resistance	43%	60%	5 648
MDR/RR-TB cases tested for resistance to second-line drugs			136
Laboratory-confirmed cases		MDR/RR-TB: 304, XDR-TB: 3	
Patients started on treatment ****		MDR/RR-TB: 238, XDR-TB: 3	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	87%	12 933
Previously treated cases, excluding relapse, registered in 2014	50%	192
HIV-positive TB cases, all types, registered in 2014	66%	41
MDR/RR-TB cases started on second-line treatment in 2013	65%	228
XDR-TB cases started on second-line treatment in 2013	33%	3

## TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	100% (100–100)

## TB financing, 2016

National TB budget (US\$ millions)

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


# Tuberculosis profile

(Rate per 100 000 population per year)



— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence


— Notified (new and relapse)

— Incidence (HIV+TB only)

## Notified cases by age group and sex, 2015



## Treatment success rate (%)



— New and relapse


— Retreatment, excluding relapse

— HIV-positive

— MDR/RR-TB

— XDR-TB

## Total budget (US\$ millions)



— Unfunded

— Funded internationally

— Funded domestically